Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation

被引:102
作者
Levine, BL [1 ]
Cotte, J
Small, CC
Carroll, RG
Riley, JL
Bernstein, WB
Van Epps, DE
Hardwick, RA
June, CH
机构
[1] USN, Med Res Inst, Immune Cell Biol Program, Bethesda, MD 20889 USA
[2] Henry M Jackson Fdn Adv Mil Med, US Mil HIV Res Program, Bethesda, MD 20889 USA
[3] Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD 20850 USA
[4] Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20889 USA
[5] Nexell Therapeut Inc, Irvine, CA 92618 USA
来源
JOURNAL OF HEMATOTHERAPY | 1998年 / 7卷 / 05期
关键词
D O I
10.1089/scd.1.1998.7.437
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We describe a procedure for large-scale enrichment, growth, and harvesting CD4+ T cells, This method may be effective for HIV-1 immunotherapy, as the mode of stimulation, with anti-CD3 plus anti-CD28 coated beads (CD3/CD28 beads) induces a potent antiviral effect. PBMC were obtained by density gradient centrifugation of an apheresis product. Monocytes/macrophages were removed by incubating PBMC with beads coated with IgG, The cells were then magnetically depleted of B cells and CD8+ cells with mouse anti-CD20 and anti-CD8 MAbs and sheep antimouse coated beads, The remaining cells were >80% CD4+ and were transferred to gas-permeable bags containing CD3/CD28 beads and cultured in a closed system. After 14 days, the cell number increased an average of 37-fold, and cells were nearly 100% CD4+, Viral load, assessed by DNA PCR for HIV-1 gag, decreased >10-fold during culture in the absence of antiretroviral agents, Removal of CD3/CD28 beads from the cell suspension was accomplished by passing cells plus beads (3-30 x 10(9) cells in 2-12 L) over a MaxSep(R) magnetic separator using gravity-driven flow, The cells were then concentrated to 300 mi in an automated centrifuge, This process allows safe and efficient growth of large numbers of CD4+ T cells from HIV-1+ donors.
引用
收藏
页码:437 / 448
页数:12
相关论文
共 39 条
  • [21] MILLER JS, 1994, BONE MARROW TRANSPL, V14, P555
  • [22] Activated long-term peripheral blood cultures as preparation for adoptive alloreactive cell therapy in cancer patients
    Morecki, S
    Gelfand, Y
    Levi, S
    Nagler, A
    Condiotti, R
    Nabet, C
    Ackerstein, A
    Slavin, S
    [J]. JOURNAL OF HEMATOTHERAPY, 1997, 6 (02): : 115 - 124
  • [23] DEVELOPMENT OF AN AUTOMATED CLOSED SYSTEM FOR GENERATION OF HUMAN LYMPHOKINE-ACTIVATED KILLER (LAK) CELLS FOR USE IN ADOPTIVE IMMUNOTHERAPY
    MUUL, LM
    NASONBURCHENAL, K
    CARTER, CS
    CULLIS, H
    SLAVIN, D
    HYATT, C
    DIRECTOR, EP
    LEITMAN, SF
    KLEIN, HG
    ROSENBERG, SA
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1987, 101 (02) : 171 - 181
  • [24] MUUL LM, 1986, J IMMUNOL METHODS, V88, P265
  • [25] LARGE-SCALE CULTURE SYSTEM OF HUMAN CD4+ HELPER KILLER T-CELLS FOR THE APPLICATION TO ADOPTIVE TUMOR-IMMUNOTHERAPY
    NAKAMURA, Y
    TOKUDA, Y
    IWASAWA, M
    TSUKAMOTO, H
    KIDOKORO, M
    KOBAYASHI, N
    KATO, S
    MITOMI, T
    HABU, S
    NISHIMURA, T
    [J]. BRITISH JOURNAL OF CANCER, 1992, 66 (01) : 20 - 26
  • [26] How immune-based interventions can change HIV therapy
    Pantaleo, G
    [J]. NATURE MEDICINE, 1997, 3 (05) : 483 - 486
  • [27] PHASE-I STUDY OF CELLULAR ADOPTIVE IMMUNOTHERAPY USING GENETICALLY MODIFIED CD8+ HIV-SPECIFIC T-CELLS FOR HIV SEROPOSITIVE PATIENTS UNDERGOING ALLOGENEIC BONE-MARROW TRANSPLANT
    RIDDELL, SR
    GREENBERG, PD
    OVERELL, RW
    LOUGHRAN, TP
    GILBERT, MJ
    LUPTON, SD
    AGOSTI, J
    SCHEELER, S
    COOMBS, RW
    COREY, L
    [J]. HUMAN GENE THERAPY, 1992, 3 (03) : 319 - 338
  • [28] T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients
    Riddell, SR
    Elliott, M
    Lewinsohn, DA
    Gilbert, MJ
    Wilson, L
    Manley, SA
    Lupton, SD
    Overell, RW
    Reynolds, TC
    Corey, L
    Greenberg, PD
    [J]. NATURE MEDICINE, 1996, 2 (02) : 216 - 223
  • [29] Riley JL, 1997, J IMMUNOL, V158, P5545
  • [30] Chemokines
    Rollins, BJ
    [J]. BLOOD, 1997, 90 (03) : 909 - 928